Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(TESSERACT): Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TBI)

NCT06110572 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT06110572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06110572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(TESSERACT): Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TBI)
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 24, 2024
Completion date
June 30, 2028
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage lung small cell carcinoma, stage iv lung cancer